Outlook Therapeutics expects December 28 results for Outlook Therapeutics stock

Published on 10/20/2026 at 22:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Four analysts set a USD 5.03 average target on October 19, 2026. Outlook Therapeutics stock costs EUR 0.48 on October 20, 2026 after hours.

Reporting date and analyst view

Outlook Therapeutics expects results around December 28, 2026.
Four analysts set an average target of USD 5.03 on October 19, 2026.
Outlook Therapeutics stock costs EUR 0.48 at Lang & Schwarz on October 20, 2026 at 10:05 p.m. CEST.

OTLK, US69012T3059, Illustration mit AI erstellt.

Outlook Therapeutics (ISIN US69012T3059) expects its next earnings report around December 28, 2026, according to SEC Tracker. The date gives investors a clear checkpoint after a sharp decline across the stock's 52-week range. At Lang & Schwarz, the stock was trading at EUR 0.48 on October 20, 2026 at 10:05 p.m. CEST.

Analysts see a wide target range

Four analysts put the average target at USD 5.03 on October 19, 2026, with targets ranging from USD 1.60 to USD 10.50, according to BullStory. The spread is substantial, so the upcoming report matters for testing whether commercialization progress is narrowing the gap between the current valuation and analyst expectations.

Nasdaq range remains wide

Paasa identifies Outlook Therapeutics as a Nasdaq-listed biotechnology company. The primary-market quote was USD 0.53 on October 20, 2026 at 3:59 p.m. ET, while the 52-week range was USD 0.16 to USD 2.54 and market capitalization was USD 129.1 million. The USD 0.53 price stood 79.13 percent below the 52-week high, underscoring the distance the company must cover before its next report.

Commercial launch remains central

Outlook Therapeutics describes LYTENAVA as its FDA-approved ophthalmic formulation of bevacizumab for wet age-related macular degeneration. The company also says Cencora provides logistics, distribution, pharmacovigilance and commercial support for the United States launch, according to Outlook Therapeutics. SEC Tracker lists an expected 10-K around December 23, 2026 and earnings around December 28, 2026, giving the reporting calendar two closely related milestones.

Euro quote after hours

The euro quotation remains the cleanest Germany-facing price marker for the report. Outlook Therapeutics was trading at EUR 0.48 at Lang & Schwarz on October 20, 2026 at 10:05 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Outlook Therapeutics stock.